Functional and clinical outcomes following omalizumab therapy
| Pretreatment | Post-treatment | p | |
| FEV1 (ml) | 1360 (955–2200) | 1850 (1270–2290) | 0.08 |
| FEV1 (% predicted) | 66% (39–73) | 74% (70–84) | 0.03 |
| Annual rate of exacerbations | 1 (1–4) | 0 (0–1) | 0.01 |
| Daily symptoms (≥2 times per week) | 15/18 patients (83%) | 8/18 patients (44%) | 0.04 |
| Nocturnal symptoms (≥2 times per week) | 15/18 patients (83%) | 4/18 patients (22%) | 0.04 |
| Oral corticosteroids | 17/18 patients (94%) | 6/18 patients (33%) | 0.0005 |
| Itraconazole | 10/18 patients (55%) | 3/18 patients (16%) | 0.037 |
Results are expressed as median with range in brackets or as a percentage. The Wilcoxon test was used to evaluate any significant differences (p<0.05) between continuous variables and the χ2 test was employed for comparison of categorical variables.